EIDD-1931 (NHC) Oral Tablets

Product Name: EIDD-1931 (NHC) Oral Tablets
Strength: 60 mg / tablet
Indications:
For the treatment of naturally occurring feline infectious peritonitis (FIP) in cats, including:
Effusive (wet) FIP
Non-effusive (dry) FIP
FIP with neurological involvement
According to clinical studies, EIDD-1931 administered at 15–20 mg/kg PO q12h for 12 weeks is a feasible treatment option for naturally occurring FIP
Active Ingredient
EIDD-1931 (β-D-N⁴-hydroxycytidine; NHC) – A nucleoside analogue antiviral agent that inhibits feline
coronavirus (FCoV) replication
Dosage and Administration
For Cats Only

Indication	Route	Dosage	Frequency
FIP Treatment	Oral (PO)	12.5 – 20 mg/kg	Every 12 hours (twice daily)

Dosage Table – 60mg Tablets

Body Weight (kg)	Dose per Administration	60mg Tablet Count	60mg Tablet Count
2.0 – 2.5	25 – 50	1/2 – 1	12.5 – 20.0
2.6 – 3.0	32.5 – 60	1/2 – 1	12.5 – 20.0
3.1 – 3.5	38.75 – 70	3/4 – 1 + 1/4	12.5 – 20.0
3.6 – 4.0	45 – 80	3/4 – 1 + 1/3	12.5 – 20.0
4.1 – 4.5	51.25 – 90	1 – 1.5	12.5 – 20.0
4.6 – 5.0	57.5 – 100	1 – 1.75	12.5 – 20.0
5.1 – 5.5	63.75 – 110	1 – 2	12.5 – 20.0
5.6 – 6.0	70 – 120	1 – 2	12.5 – 20.0
> 6.0	Calculate by weight	Use combination as	12.5 – 20.0

Administration Instructions
1.Administer orally with or without food
2.Tablets may be given whole or crushed and mixed with a small amount of food 3.Oral solution should be measured accurately using the provided dosing syringe
4.Administer every 12 hours (twice daily) for a minimum of 12 weeks
5.Do not skip doses to ensure optimal therapeutic effect

Precautions
1.This is a prescription drug and must be used under veterinary supervision
2.Monitor complete blood count (CBC) and liver enzymes (ALT) during treatment
3.Discontinue treatment if severe neutropenia or persistent ALT elevation occurs
4.Not recommended for use in pregnant or lactating cats (safety not established)
5.Keep out of reach of children
6.For animal use only

Mechanism of Action
EIDD-1931 (NHC) is the active nucleoside form of the prodrug molnupiravir (EIDD-2801). It acts as a
potent inhibitor of feline coronavirus (FCoV) replication by inducing lethal mutagenesis during viral RNA
synthesis. Studies have confirmed its effectiveness against both FIPV serotypes I and II in vitro . Plasma
levels sufficient to inhibit viral replication are achieved following oral administration .

Treatment Response
According to clinical studies (Kennedy et al., 2026):
All cats (9/9) with naturally occurring FIP showed a complete response to treatment
Response observed in both effusive and non-effusive forms, including neurological involvement
Median dose of 16.2 mg/kg (range 12.0–20.5 mg/kg) administered PO q12h for 12 weeks
Treatment success sustained for >12 months post-discontinuation in most cats

Drug Interactions
EIDD-1931 may influence CYP3A4 and CYP2C8 enzyme activity
Caution should be exercised when co-administered with other medications metabolized by these pathways Potential for disease-state dependent pharmacokinetic alterations

Note on Pharmacokinetics
EIDD-1931 is the active metabolite of the prodrug molnupiravir (EIDD-2801). Oral administration
of EIDD-1931 achieves plasma levels greater than the EC₅₀ values established for FIPV inhibition
in vitro . Disease states such as liver injury or gastric injury may affect drug exposure and
clearance, potentially requiring dose adjustment

Package:
Tablets: Aluminum-plastic blister pack, 10 tablets per blister
Storage:
Store at controlled room temperature 20° to 25°C (68° to 77°F). Protect from freezing. Use contents
within 90 days of first puncture.
Shelf life:
2 years

For animal use only.

Product Name: Feline Parvovirus Inhibitor Tablets
Indication: For the specific treatment of Feline Panleukopenia (Feline Parvovirus, FPV) infection in cats.
This product is a first-line therapeutic agent designed to directly inhibit FPV replication, rapidly reduce viral
load, and is a core component of the standard treatment protocol for feline panleukopenia.
It must be initiated as early as possible upon diagnosis and used in conjunction with comprehensive
supportive care (including intravenous fluid therapy, antibiotics, antiemetics, etc.) to achieve optimal
therapeutic outcomes.
Dosage: For oral use only.
The recommended dosage is 1 tablet per 4 kg of body weight, administered every 12 hours.
Duration of Treatment: The recommended treatment course is 5 to 7 days.
Administration should continue for at least 72 hours after the complete resolution of clinical symptoms and until two consecutive negative fecal antigen tests are obtained, as determined by the attending veterinarian.

Body weight of cats (kg)	Dosage per Administration	Administration Interval
BW≤2	½ tablet	Twice a day (every 12 hours)
2<BW≤4	1 tablet
4<BW≤8	1.5 tablets
8≤BW	According to weight, 1/4 tablet per kg

Withdrawal:
Not applicable
Package:
30 tablets per bottle
Storage:
Store tightly sealed below 25℃
Shelf life: 2 years
Warning：
This product contains a highconcentration, last-resort antibiotic.
Accidental ingestion by humans may cause serious health effects and contribute to antibiotic resistance. Seek medical advice immediately if ingested.

Important Notes
(1)Prescription-only: This is a prescription-only medicine. Administration MUST be under the direct supervision and guidance of a veterinarian.
(2)Complete the Course: Even if symptoms improve, administer the full course as prescribed to prevent
relapse and resistance development.
(3)Monitoring: Regular monitoring of renal function and overall clinical response is essential during treatment.
(4)Adverse Reactions: Potential side effects may include vomiting, diarrhea, loss of appetite, or in rare cases neurological signs (e.g., tremors). Discontinue use and contact your veterinarian immediately if adverse reactions occur.
(5)THERAPEUTIC WARNING: While this product is a specific antiviral agent, the successful management of feline panleukopenia critically depends on timely and aggressive supportive care to address dehydration, secondary infections, and nutritional support. This product does not replace essential fluid and electrolyte therapy.

For animal treatment only.

Product Name: FPV Comprehensive Support Tablets
Indication: For the auxiliary/supportive treatment of Feline Panleukopenia (FPV) in cats.
Helps to improve appetite, reduce vomiting and diarrhea symptoms.
Supports immune system function and promotes the regeneration of white blood cells.
Provides essential nutrients to prevent secondary complications due to malnutrition.
Dosage: For oral use only.
The recommended dosage is 1 tablet per 4 kg of body weight, administered every 12 hours.
Duration of Treatment: The recommended treatment course is 5 to 7 days.
Administration should continue for at least 72 hours after the complete resolution of clinical symptoms and until two consecutive negative fecal antigen tests are obtained, as determined by the attending veterinarian.

Body weight of cats (kg)	Dosage per Administration	Administration Interval
BW≤2	½ tablet	Twice a day (every 12 hours)
2<BW≤4	1 tablet
4<BW≤8	1.5 tablets
8≤BW	According to weight, 1/4 tablet per kg

Important Notes
(1)Prescription-only: This is a prescription-only medicine. Administration MUST be under the direct supervision and guidance of a veterinarian.
(2)Complete the Course: Even if symptoms improve, administer the full course as prescribed to prevent
relapse and resistance development.
(3)Monitoring: Regular monitoring of renal function and overall clinical response is essential during treatment.
(4)Adverse Reactions: Potential side effects may include vomiting, diarrhea, loss of appetite, or in rare cases eurological signs (e.g., tremors). Discontinue use and contact your veterinarian immediately if adverse reactions occur.
(5)THERAPEUTIC WARNING: While this product is a specific antiviral agent, the successful management of feline panleukopenia critically depends on timely and aggressive supportive care to address dehydration, secondary infections, and nutritional support. This product does not replace essential fluid and electrolyte therapy.

For animal treatment only.

Product Name: Meropenem
Indication: Treatment of severe systemic/localized infections caused by multidrug-resistant bacteria (pneumonia, pyelonephritis, peritonitis, deep pyoderma, wounds, septicemia).
Dosage: For oral use only.
15 mg/kg every 8–12 hours.

Body weight of cats (kg)	Dosage per Administration	Administration Interval
1≤BW≤3	15 – 45 mg	Twice a day (every 8-12 hours)
3<BW≤6	45 – 90 mg
6<BW≤10	90 – 150 mg
10≤BW	Calculate at 15 mg/kg

Product Name: Feline Parvovirus Inhibitor Tablets
Indication: Specific treatment for FPV (Feline Panleukopenia). Directly inhibits viral replication. Must be combined with supportive care (fluids, antibiotics, antiemetics).
Dosage: For oral use only.
1 tablet per 4 kg every 12 hours. Course: 5–7 days.

Body weight of cats (kg)	Dosage per Administration	Administration Interval
BW≤2	½ tablet	Twice a day (every 12 hours)
2<BW≤4	1 tablet
4<BW≤8	1.5 tablets
8≤BW	¼ tablet per kg

Product Name: FPV Comprehensive Support Tablets
Indication: Supportive treatment for FPV. Improves appetite, reduces vomiting/diarrhea, supports immune function and white blood cell regeneration, prevents malnutrition.
Dosage: For oral use only.
1 tablet per 4 kg every 12 hours. Course: 5–7 days.
Dosage Table

Same as above.

Product Name: Feline Parvovirus Inhibitor Tablets
Indication: Specific treatment for FPV (Feline Panleukopenia). Directly inhibits viral replication. Must be combined with
supportive care (fluids, antibiotics, antiemetics).
Dosage: For oral use only.
1 tablet per 4 kg every 12 hours. Course: 5–7 days.

Product Name: CheerVitin Tablets
Indication: Treatment/management of FIV infection. Inhibits viral replication, improves chronic tomatitis, recurrent
infections, and quality of life.
Dosage: For oral use only.
Same as above: 1 tablet per 4 kg every 12 hours. Course: 5–7 days.
Dosage Table
Same as above.

Important Notes
Prescription-only
Complete the full course even if symptoms improve
Possible adverse reactions: vomiting, diarrhea, loss of appetite; rarely neurological signs (e.g., tremors)
Accidental ingestion by humans: seek medical advice immediately

Storage:
Store tightly sealed below 25℃
Shelf life: 2 years

For animal treatment only.

Product Name：FPV/CPV-2 Injejction
Product Characteristics: Colorless to light yellow clear liquid
Pharmacological Action: This product specifically neutralizes the feline parvovirus (FPV), blocks virus replication， and restores immune
system function， thereby achieving the therapeutic effect on FPV.
Indications： Used for the prevention and treatment of FPV. Especially suitable for cats showing early clinical symptoms (such as vomiting，diarrhea， fever， listlessness， and loss of appetite).
Usage and Dosage：
Administration Route： Intramuscular injection or oral tablet
Dosage: 1 ml per kilogram of body weight (or 1 tablet per kilogram of body weight)
Dosage frequency: Twice daily
Course of treatment: Use continuously without interruption for 3 days.

Body Weight (kg)	Dose per Administration	Daily dosage	Total dose on the 3 days
0.5 kg	0.5 ml	1.0 ml	3.0 ml
1.0 kg	1.0 ml	2.0 ml	6.0 ml
1.5 kg	1.5 ml	3.0 ml	9.0 ml
2.0 kg	2.0 ml	4.0 ml	12.0 ml
2.5 kg	2.5 ml	5.0 ml	15.0 ml
3.0 kg	3.0 ml	6.0 ml	18.0 ml
3.5 kg	3.5 ml	7.0 ml	21.0 ml
4.0 kg	4.0 ml	8.0 ml	24.0 ml
4.5 kg	4.5 ml	9.0 ml	27.0 ml
5.0 kg	5.0 ml	10.0 ml	30.0 ml
5.5 kg	5.5 ml	11.0 ml	33.0 ml
6.0 kg	6.0 ml	12.0 ml	36.0 ml
6.5 kg	6.5 ml	13.0 ml	39.0 ml
7.0 kg	7.0 ml	14.0 ml	42.0 ml
7.5 kg	7.5 ml	14.0 ml	45.0 ml
8.0 kg	8.0 ml	15.0 ml	48.0 ml

Clinical data:
According to the results of the multi-center clinical study conducted in China in 2025, it was found that:
If this product is used in the early stage of feline distemper (within 24 hours after the onset of clinical symptoms), the survival rate will exceed 99.5%.
After taking the medicine, no serious adverse reactions were observed.
For the cats that completed the 3-day treatment course consecutively, their clinical symptoms (vomiting, diarrhea, fever) were significantly alleviated, and their white blood cell count returned to the normal range.

Clinical conclusion:
If this product is injected or the oral tablets are administered to cats in the early stage of feline distemper, it can effectively prevent the death of the cats.

Notes:
This product is only applicable to patients in the early stage of feline fever. If the condition has progressed to severe shock, extremely low ody temperature, disseminated intravascular coagulation (DIC), or other terminal stages, the therapeutic effect may be limited.
During use, it is recommended to combine with supportive therapies (such as fluid replacement, temperature maintenance, and electrolyte balance maintenance, etc.).
This product should not be used by those who are allergic to any of its ingredients (the ingredients will be clarified later and a supplement will
be provided).
The safety data for pregnant and lactating cats is not yet sufficient. It is recommended to use under the guidance of a veterinarian.
This product is not applicable for vomiting or leukopenia caused by factors other than feline distemper.

Adverse reactions:
During the clinical study, mild injection site swelling or transient drowsiness was occasionally observed, but no treatment was necessary as
these symptoms would resolve on their own. No serious adverse reactions were noted.

Storage conditions:
Injection: Store refrigerated at 2℃ to 8℃, protected from light, and avoid freezing.
Expiration date: 24 months

For animal use only.

Product Name: CheerVitin Tablets
Indication: Specifically for the treatment and management of Feline Immunodeficiency Virus (FIV) infection.
Effectively inhibits viral replication, slows disease progression, improves clinical signs (such as chronic stomatitis, recurrent infections), and enhances the quality of life and life expectancy of infected cats.
Dosage: For oral use only.
The recommended dosage is 1 tablet per 4 kg of body weight, administered every 12 hours.
Duration of Treatment: The recommended treatment course is 5 to 7 days.
Administration should continue for at least 72 hours after the complete resolution of clinical symptoms and until two consecutive negative fecal antigen tests are obtained, as determined by the attending veterinarian.

Body Weight (kg)	Dose per Administration	Administration Interval
BW≤2	½ tablet	Twice a day (every 12 hours)
2<BW≤4	1 tablet
4<BW≤8	1.5 tablets
8≤BW	According to weight, 1/4 tablet per kg

Important Notes
(1)Prescription-only: This is a prescription-only medicine.
Administration MUST be under the direct supervision and guidance of a veterinarian.
(2)Complete the Course: Even if symptoms improve, administer the full course as prescribed to prevent
relapse and resistance development.
(3)Monitoring: Regular monitoring of renal function and overall clinical response is essential during treatment.
(4)Adverse Reactions: Potential side effects may include vomiting, diarrhea, loss of appetite, or in rare cases neurological signs (e.g., tremors). Discontinue use and contact your veterinarian immediately if adverse reactions occur.
(5)THERAPEUTIC WARNING: While this product is a specific antiviral agent, the successful management of feline panleukopenia critically depends on timely and aggressive supportive care to address dehydration, secondary infections, and nutritional support. This product does not replace essential fluid and electrolyte therapy.

For animal treatment only.

Product Name: GS-441524 Tablet
Strength: Each tablet contains 45mg / 60mg / 75mg of GS-441524
Package: 10 PCS/box
For Use In: Cats

Actions & Indications:
For the treatment of naturally occurring feline infectious peritonitis in cats, including:
Effusive (wet) FIP
Non-effusive (dry) FIP
FIP with ocular or neurological involvement (dose adjustment may be required)

Dosage:
Recommended Dosage
4.0 mg/kg body weight, once every 24 hours, by subcutaneous injection
Treatment Duration
At least 12 consecutive weeks

Body weight (kg)	Dose per Administration(mg)	45mg Tablet Count	60mg Tablet Count	75mg Tablet Count
1.0-2.0	4-8	½ – 1	/	/
2.0-3.0	8-12	1-1.5	/	/
3.0-40	12-16	1.5-2	1	/
4.0-5.0	16-20	2-2.5	1-1.5	1
5.0-6.0	20-24	2.5-3	1.5-2	1-1.5
6.0-7.0	24-28	3-3.5	2-2.5	1.5-2
>7.0	Calculate by weight	Proportional combination	Proportional combination	Proportional combination

Administration Instructions:
Tablets may be swallowed whole or crushed and mixed with a small amount of food. Administration with food is recommended to enhance absorption stability.

Adverse Reactions:
Injection Site Reactions
Mild gastrointestinal upset (vomiting, decreased appetite) may occur in rare cases, typically transient

Adverse Reactions:
Mild elevations in BUN and SDMA observed in rare cases, reversible upon discontinuation
No persistent abnormalities in liver/kidney function or complete blood count
No observable effects on permanent tooth development in kittens

Precautions:
1.This is a prescription drug and must be used under veterinary supervision
2.Regular monitoring of body weight, serum albumin, A/G ratio, and complete blood count is recommended during treatment
3.For cats with ocular or neurological signs, individualized treatment plans should be developed under specialist supervision
4.The injectable solution has a low pH (approximately 1.5) and may cause transient pain upon injection; rotation of injection sites is recommended
5.Not recommended for use in pregnant or lactating cats due to insufficient safety data

Discontinuation:
After treatment completion, observation for at least 3 months is recommended. Veterinary re-evaluation is advised if any of the following occur:
Weight loss
Fever
Decreased appetite
Lethargy
Abdominal distension or dyspnea

Package:Aluminum-plastic blister pack, 10 tablets per box
Storage:Store tightly sealed below 25℃
Shelf life: 2 years

For animal use only.

Product Name: Canine Parvovirus(CPV) Inhibitor Tablets

Indication: For the specific treatment of Canine Parvovirus(CPV) infection in cats.
This product is a first-line therapeutic agent designed to directly inhibit Canine Parvovirus(CPV) replication,rapidly reduce viral load, and is a core component of the standard treatment protocol for feline panleukopenia.
It must be initiated as early as possible upon diagnosis and used in conjunction with comprehensive
supportive care (including intravenous fluid therapy, antibiotics, antiemetics, etc.) to achieve optimal therapeutic outcomes.

Dosage: For oral use only.
The recommended dosage is 1 tablet per 4 kg of body weight, administered every 12 hours.
Duration of Treatment: The recommended treatment course is 5 to 7 days.
Administration should continue for at least 72 hours after the complete resolution of clinical symptoms and until two consecutive negative fecal antigen tests are obtained, as determined by the attending veterinarian.

Body weight of dogs (kg)	Dosage per Administration	Administration Interval
BW≤2	½ tablet	Twice a day (every 12 hours)
2<BW≤4	1 tablet
4<BW≤8	1.5 tablets
8≤BW	According to weight, 1/4 tablet per kg

Withdrawal:
Not applicable
Package:
30 tablets per bottle
Storage:
Store tightly sealed below 25℃
Shelf life: 2 years
Warning：
This product contains a highconcentration, last-resort antibiotic.Accidental ingestion by humans may cause serious health effects and contribute to antibiotic resistance. Seek medical advice immediately if ingested.

Important Notes
(1)Prescription-only: This is a prescription-only medicine.Administration MUST be under the direct supervision and guidance of a veterinarian.
(2)Complete the Course: Even if symptoms improve, administer the full course as prescribed to prevent relapse and resistance development.
(3)Monitoring: Regular monitoring of renal function and overall clinical response is essential during treatment.
(4)Adverse Reactions: Potential side effects may include vomiting, diarrhea, loss of appetite, or in rare cases neurological signs (e.g., tremors). Discontinue use and contact your veterinarian immediately if adverse reactions occur.
(5)THERAPEUTIC WARNING: While this product is a specific antiviral agent, the successful management of feline panleukopenia critically depends on timely and aggressive supportive care to address dehydration, secondary infections, and nutritional support. This product does not replace essential fluid and electrolyte therapy.

For animal use only.

Product Name: GS-441524 Sterile Injection
Strength: 20mg/ml × 6ml; 20mg/ml × 8ml; 20mg/ml × 10ml; 30mg/ml × 6ml; 30mg/ml × 8ml; 30mg/ml ×10ml
Package: 10 PCS/box
For Use In: Cats
Actions & Indications:
For the treatment of naturally occurring feline infectious peritonitis in cats, including:
Effusive (wet) FIP
Non-effusive (dry) FIP
FIP with ocular or neurological involvement (dose adjustment may be required)

Dosage:
Recommended Dosage
4.0 mg/kg body weight, once every 24 hours, by subcutaneous injection
Treatment Duration
At least 12 consecutive weeks

Body weight (kg)	Dose per Administration(mg)	Volume for 20mg/ml (ml)	Volume for 30mg/ml (ml)
1.0-2.0	4-8	0.2-0.4	0.13-0.27
2.0-3.0	8-12	0.4-0.6	0.27-0.40
3.0-40	12-16	0.6-0.8	0.40-0.53
4.0-5.0	16-20	0.8-1.0	0.53-0.67
5.0-6.0	20-24	1.0-1.2	0.67-0.80
6.0-7.0	24-28	1.2-14	0.80-0.93
>7.0	Calculate by weight	Proportional	Proportional

Special Dosage Instructions:
Forcatswithocular orneurologicalsigns,adosageof4.0 mg/kgorhigherisrecommendedunder veterinarysupervision,withconsiderationofextendedtreatmentduration.

Treatment Response:
Accordingtoclinicalstudies (Pedersen et al., 2019):
Bodytemperaturereturnsto normal within 12–36hours in most cats
Appetite,activity level, andbody weight improve significantly within 1–2 weeks
Abdominalorthoracic effusion resolves graduallywithin 1–2 weeks
Serumalbumin andA/Gratio normalizewithin 8–10 weeks
Over80%ofcats completing 12weeksormore of treatment achieve long-term
Adverse Reactions:
InjectionSiteReactions
Localswelling, scabbing,or ulceration,mostcommon in the first few weeks of treatment
Incidenceapproximately60%,withopensores occurringin about25%ofcases
Usuallyhealwithin2weekswithsupportivecare(local cleaning, rotation of injection sites)

Precautions:
1.This is a prescription drug and must be used under veterinary supervision
2.Regular monitoring of body weight, serum albumin, A/G ratio, and complete blood count is recommended during treatment
3.For cats with ocular or neurological signs, individualized treatment plans should be developed under specialist supervision
4.The injectable solution has a low pH (approximately 1.5) and may cause transient pain upon injection;rotation of injection sites is recommended
5.Not recommended for use in pregnant or lactating cats due to insufficient safety data

For animal use only.